Takeda, PE firm launch GI-focused pharmaceutical company — 3 insights

Takeda and Frazier Healthcare Partners launched Phathom Pharmaceuticals to develop gastrointestinal treatments.

What you should know:

1. Phathom will develop and commercialize Takeda's potassium competitive acid blocker, vonoprazan, in the U.S., Europe and Canada.

2. Frazier led a $90 million financing round supported by several other investors.

3. Phathom then took out a $50 million loan through Silicon Valley Bank to support developmental efforts.

More articles on gastroenterology:
CHI Franciscan to divest ASC, pay $2.5M to settle anticompetitive lawsuit: 5 things to know
Surgery Partners reports $417M in revenue & more — 10 ASC industry notes
As investors favor ASCs & offices, major skilled nursing operator splits segments

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months